{"entity":{"id":"rtog-0129","kind":"trial","name":"RTOG 0129 (HPV analysis)","aka":[],"tldr":"The analysis that showed HPV-positive throat cancers are a different, far more curable disease, launching two decades of de-escalation research.","summary":"Ang et al., NEJM 2010: 3-year OS 82.4% for HPV-positive vs 57.1% for HPV-negative oropharyngeal cancer; HPV status was the strongest prognostic factor, with tobacco exposure modifying it. Led to a separate AJCC staging system for HPV-positive disease (8th edition) and the de-escalation trials that followed.","status":"completed","asOf":"2026-09-07","links":[{"label":"ClinicalTrials.gov NCT00047008","url":"https://clinicaltrials.gov/study/NCT00047008"},{"label":"NEJM 2010","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa0912217"}],"tags":[],"related":[],"cancers":["head-and-neck","hpv-positive-oropharyngeal-cancer"],"sections":[],"technologies":["imrt-igrt","hpv-vaccine"],"targets":[],"drugs":[],"companies":["nrg-oncology"],"institutions":[],"pathways":[],"terms":["hpv-p16"],"trials":[],"people":["maura-gillison","everett-vokes"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT00047008","phase":"3","setting":"Stage III-IV oropharyngeal and other HNSCC: accelerated vs standard fractionation chemoradiation; retrospective HPV analysis","sponsor":"RTOG / NCI","result":"3-year OS 82.4% (HPV+) vs 57.1% (HPV-).","started":"2002-07","startedType":"actual","yearReported":2010,"enrolled":743,"enrolledBasis":"registry","outcomes":[{"endpoint":"Overall survival at 3 years by HPV status","unit":"%","arms":[{"name":"HPV-positive","value":82.4},{"name":"HPV-negative","value":57.1}],"source":"https://www.nejm.org/doi/full/10.1056/NEJMoa0912217"}],"replication":"Replicated across TROG, DAHANCA, and De-ESCALaTE cohorts."},"route":"/trials/rtog-0129/","neighbours":{"cancer":[{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"},{"id":"hpv-positive-oropharyngeal-cancer","kind":"cancer","name":"HPV-positive oropharyngeal cancer","route":"/cancers/hpv-positive-oropharyngeal-cancer/"}],"technology":[{"id":"hpv-vaccine","kind":"technology","name":"HPV & HBV vaccination","route":"/technologies/hpv-vaccine/"},{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/"}],"company":[{"id":"nrg-oncology","kind":"company","name":"NRG Oncology","route":"/companies/nrg-oncology/"}],"term":[{"id":"hpv-p16","kind":"term","name":"HPV-positive (p16) head and neck cancer","route":"/terms/hpv-p16/"}],"person":[{"id":"everett-vokes","kind":"person","name":"Everett E. Vokes","route":"/people/everett-vokes/"},{"id":"maura-gillison","kind":"person","name":"Maura L. Gillison","route":"/people/maura-gillison/"}]}}